Granted Patent
B2
US 12,583,926 · App. 18/770,712 · Granted Mar 24, 2026
CD47/pd-L1-targeting protein complex and methods of use thereof
Inventors:
Jiin-Tarng Wang (Taichung City, TW); Han-Fang Teng (New Taipei City, TW); Yun-Chih Cheng (Taipei, TW); Pan-Hsien Kuo (Taoyuan City, TW); Chieh-Hsin Ho (Taipei, TW); Wei-Tse Sun (Taipei, TW); Chia-Zhen Wu (Taipei, TW); Tsai-Kuei Shen (Taipei, TW); Chi-Ling Tseng (Taipei City, TW); Zong Sean Juo (New Taipei City, TW)
Assignee:
FBD Biologics Limited
View Patent ↗
Loading inventors, assignments & file history…
Abstract
This disclosure relates to protein complexes targeting CD47, PD-L1, and/or TGFβ, and methods of use thereof. In one aspect, the protein complexes include a CD47-binding domain having all or a portion of the SIRPα extracellular region; a PD-L1-binding domains having a VHH that binds to PD-L1; and optionally a TGFβ-binding domain having all or a portion of the TGFBRII extracellular region.
Claims (19)
1 . A protein complex, comprising
(a) a first polypeptide comprising from N-terminus to C-terminus: a first CD47-binding domain, a first VHH that binds to PD-L1, a first Fc region, and a first TGFβ-binding domain; and
(b) a second polypeptide comprising from N-terminus to C-terminus: a second CD47-binding domain, a second VHH that binds to PD-L1, a second Fc region, and a second TGFβ-binding domain,
wherein the first VHH and the second VHH comprise a sequence that is identical to SEQ ID NO: 8; wherein the first CD47-binding domain and the second CD47-binding domain comprise a sequence that is identical to SEQ ID NO: 7; wherein the first TGFβ-binding domain and the second TGFβ-binding domain comprise a sequence that is identical to SEQ ID NO: 9.
2 . The protein complex of claim 1 , wherein the first polypeptide and the second polypeptide comprise a sequence that is identical to SEQ ID NO: 1 or 2.
3 . A protein conjugate comprising the protein complex of claim 1 , covalently bound to a therapeutic agent.
4 . A pharmaceutical composition comprising the protein complex of claim 1 , and a pharmaceutically acceptable carrier.
5 . A nucleic acid comprising a polynucleotide encoding the protein complex of claim 1 .
6 . A vector comprising the nucleic acid of claim 5 .
7 . A cell comprising the nucleic acid of claim 5 .
8 . A method of producing a protein complex, the method comprising
(a) culturing the cell of claim 7 under conditions sufficient for the cell to produce the protein complex; and
(b) collecting the protein complex produced by the cell.
9 . A method of treating a subject having cancer, the method comprising administering a therapeutically effective amount of a composition comprising the protein complex of claim 1 , to the subject.
10 . The method of claim 9 , wherein the subject has a cancer cell expressing CD47 or PD-L1.
11 . The method of claim 9 , wherein the cancer is breast cancer, prostate cancer, non-small cell lung cancer, pancreatic cancer, diffuse large B-cell lymphoma, mesothelioma, lung cancer, ovarian cancer, colon cancer, pleural tumor, glioblastoma, esophageal cancer, gastric cancer, synovial sarcoma, thymic carcinoma, endometrial carcinoma, stomach cancer, cholangiocarcinoma, head and neck cancer, blood cancer, or a combination thereof.
12 . The method of claim 9 , wherein the cancer is a solid tumor.
13 . A method of decreasing the rate of tumor growth or killing a tumor cell, the method comprising
contacting a tumor cell with an effective amount of a composition comprising the protein complex of claim 1 .
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 18, 2025
From: WANG, JIIN-TARNG; TENG, HAN-FANG; CHENG, YUN-CHIH; KUO, PAN-HSIEN; HO, CHIEH-HSIN; SUN, WEI-TSE; WU, CHIA-ZHEN; SHEN, TSAI-KUEI; TSENG, CHI-LING; JUO, ZONG SEAN
To: FBD BIOLOGICS LIMITED
Reel/Frame 072950/0264 →
Continuity (3)
Continuation
PCTCN2024096554
· May 31, 2024
Provisional Application
63470003
· May 31, 2023
References Cited (129)
US 8728474B2
· Honjo et al.
· 2014
[cited by applicant]
US 9834606B2
· Li et al.
· 2017
[cited by applicant]
US 9944911B2
· Ring et al.
· 2018
[cited by applicant]
US 9969789B2
· Uger et al.
· 2018
[cited by applicant]
US 20060275844A1
· Linke et al.
· 2006
[cited by applicant]
US 20080280297A1
· Dalla-Favera et al.
· 2008
[cited by applicant]
US 20110190157A1
· Kipps et al.
· 2011
[cited by applicant]
US 20120178111A1
· Diamandis et al.
· 2012
[cited by applicant]
US 20130017199A1
· Langermann
· 2013
[cited by applicant]
US 20170247454A1
· Benz et al.
· 2017
[cited by applicant]
US 20170247476A1
· Yan et al.
· 2017
[cited by applicant]
US 20200087377A1
· Yue
· 2020
[cited by applicant]
US 20240228584A1
· Jiin-Tarng et al.
· 2024
[cited by applicant]
US 20240360219A1
· Wang et al.
· 2024
[cited by applicant]
AU 2013362789B2
· 2018
[cited by applicant]
AU 2016210755B2
· 2021
[cited by applicant]
CN 104136037B
· 2018
[cited by applicant]
CN 108350048A
· 2018
[cited by applicant]
CN 106146670B
· 2019
[cited by applicant]
CN 105073780B
· 2019
[cited by applicant]
CN 112940134A
· 2021
[cited by applicant]
CN 113004414A
· 2021
[cited by applicant]
CN 113968903A
· 2022
[cited by applicant]
CN 114375310A
· 2022
[cited by applicant]
CN 115397853A
· 2022
[cited by applicant]
CN 117597141A
· 2024
[cited by applicant]
EP 3287470A1
· 2018
[cited by applicant]
EP 3331902
· 2018
[cited by applicant]
EP 2931752B1
· 2019
[cited by applicant]
EP 2804617B1
· 2020
[cited by applicant]
EP 3128005B1
· 2021
[cited by applicant]
EP 3575326B1
· 2022
[cited by applicant]
WO WO2008077546
· 2008
[cited by applicant]
WO WO2008157367
· 2008
[cited by applicant]
WO WO2011109789A2
· 2011
[cited by examiner]
WO WO2013109752
· 2013
[cited by applicant]
WO WO2014094122
· 2014
[cited by applicant]
WO WO2015027082
· 2015
[cited by applicant]
WO WO2016023040
· 2016
[cited by applicant]
WO WO2016169261A1
· 2016
[cited by applicant]
WO WO2017027422
· 2017
[cited by applicant]
WO WO2017027422A1
· 2017
[cited by examiner]
WO WO2018094173
· 2018
[cited by applicant]
WO WO2019084692A1
· 2019
[cited by applicant]
WO WO2019096121A1
· 2019
[cited by examiner]
WO WO2020233539A1
· 2020
[cited by applicant]
WO WO2021005599
· 2021
[cited by applicant]
WO WO2021041886
· 2021
[cited by applicant]
WO WO2021081258
· 2021
[cited by applicant]
WO WO2021185337A1
· 2021
[cited by applicant]
WO WO2022063316
· 2022
[cited by applicant]
WO WO2022177394A1
· 2022
[cited by applicant]
WO WO2023140950A1
· 2023
[cited by applicant]
WO WO2024140998A2
· 2024
[cited by examiner]
WO WO2024193635A1
· 2024
[cited by examiner]
Chen et al., Generation and analysis of random point mutations in an antibody CDR2 sequence: many mutated antibodies lose their ability to bind antigen; 1992, J. Experimental Medicine, 176:855-866. (Year: 1992).
[cited by examiner]
MacCallum et al., Antibody-antigen interactions: contact analysis and binding site topography, 1996, J. Mol. Biol., 262: 732-745. (Year: 1996).
[cited by examiner]
Lee et al., Novel structural determinants on SIRPa that mediate binding to CD47; 2007, J. Immunology, 179(11): 7741-7750. (Year: 2007).
[cited by examiner]
Liu et al., Dual targeting of innate and adaptive checkpoints on tumor cells limits immune evasion; 2018, Cell Reports, 24: 2101-2111. (Year: 2018).
[cited by examiner]
Qu et al., Targeting CD47/SIRPa as a therapeutic strategy, where we are and where we are headed; 2022; Biomarker Research, 10:20 1-18. (Year: 2022).
[cited by examiner]
Baxevanis, “Antibody-based cancer therapy,” Expert Opinion on Drug Discovery, Apr. 2008, 3(4):441-52.
[cited by applicant]
Bierie et al., “TGFβ: the molecular Jekyll and Hyde of cancer,” Nature Reviews Cancer, Jul. 2006, 6(7):506-20.
[cited by applicant]
Chowdhury et al., “Epigenetic targeting of transforming growth factor β receptor II and implications for cancer therapy,” Molecular and Cellular Pharmacology, Jan. 2009, 1(1):57, 19 pages.
[cited by applicant]
De Crescenzo, “Three key residues underlie the differential affinity of the TGFβ isoforms for the TGFβ type II receptor,” Journal of Molecular Biology, Jan. 2006, 355(1):47-62.
[cited by applicant]
Dhanda et al., “Development of a strategy and computational application to select candidate protein analogues with reduced HLA binding and immunogenicity,” Immunology, Jan. 2018, 153(1):118-32.
[cited by applicant]
EP Extended European Search Report in European Appln. No. 24150099.0, mailed on Jun. 6, 2024, 8 pages.
[cited by applicant]
Gatti-Mays et al., “M7824: a promising new strategy to combat cancer immune evasion,” Oncoscience, Nov. 2018, 5(11-12):269-70.
[cited by applicant]
GenBank Acession No. NP_542970.1, “tyrosine-protein phosphatase non-receptor type substrate 1 isoform 1 precursor [
[cited by applicant]
Ha et al., “Immunoglobulin Fc heterodimer platform technology: from design to applications in therapeutic antibodies and proteins,” Frontiers in Immunology, Oct. 2016, 7:394, 16 pages.
[cited by applicant]
Han et al., “PD-1/PD-L1 pathway: current researches in cancer,” American Journal of Cancer Research, 2020 10(3):727-42.
[cited by applicant]
Hirano et al., “Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity,” Cancer Research, Feb. 2005, 65(3):1089-96.
[cited by applicant]
Huang (Computation and Structural Biotechnology Journal, vol. 19, p. 5494-5503, 2021) (Year: 2021).
[cited by applicant]
Huang et al. “Regulation of CD47 expression in cancer cells,” Translational Oncology, Dec. 2020, 13(12): 100862, 7 pages.
[cited by applicant]
Jiang et al., “Targeting CD47 for cancer immunotherapy,” Journal of Hematology & Oncology, Dec. 2021, 14(1), 18 pages.
[cited by applicant]
Kim et al, “Novel therapies emerging in oncology to target the TGF-β pathway,” Journal of Hematology & Oncology, Dec. 2021, 14, 20 pages.
[cited by applicant]
Kwok et al., “Pembrolizumab (keytruda),” Human Vaccines & Immunotherapeutics, Nov. 2016, 12(11):2777-89.
[cited by applicant]
Lei et al., “Resistance mechanisms of anti-PD1/PDL1 therapy in solid tumors,” Frontiers in Cell and Developmental Biology, Jul. 2020, 8:672.
[cited by applicant]
Lind et al, “Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances,” Journal for Immunotherapy of Cancer, Feb. 2020, 8(1), 10 pages.
[cited by applicant]
Liu et al. “PD-1/PD-L1 checkpoint inhibitors in tumor immunotherapy,” Frontiers in Pharmacology, Sep. 2021, 12, 8 pages.
[cited by applicant]
NCBI Accession No. AAH26692.1, “SIRPA protein [
[cited by applicant]
NCBI Accession No. NP_003233.4, “TGF-beta receptor type-2 isoform B precursor [
[cited by applicant]
NCBI Accession No. NP_005009.2, “programmed cell death protein 1 precursor [
[cited by applicant]
PCT International Preliminary Report on Patentability in International Appln. No. PCT/US2022/053125, mailed on Mar. 16, 2024, 12 pages.
[cited by applicant]
PCT International Search Report and Written Opinion in International Appln. No. PCT/CN2023/140179, mailed on Jan. 24, 2024, 14 pages.
[cited by applicant]
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2022/052373, mailed on Jun. 15, 2023, 15 pages.
[cited by applicant]
Powles et al., “MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer,” Nature, Nov. 2014, 515(7528): 558-562.
[cited by applicant]
Raedler et al., “Keytruda (pembrolizumab): first PD-1 inhibitor approved for previously treated unresectable or metastatic melanoma,” American Health & Drug Benefits, Mar. 2015, 8(Spec Feature):96, 5 pages.
[cited by applicant]
Seiffert et al., “Signal-regulatory protein α (SIRPα) but not SIRPβ is involved in T-cell activation, binds to CD47 with high affinity, and is expressed on immature CD34+ CD38− hematopoietic cells,” Blood, The Journal o…
[cited by applicant]
Shimabukuro-Vornhagen et al., “Cytokine release syndrome,” Journal for Immunotherapy of Cancer, Dec. 2018, 6:56, 14 pages.
[cited by applicant]
Sikic et al., “First-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers,” Journal of Clinical Oncology, Apr. 2019, 37(12):946, 11 pages.
[cited by applicant]
Topalian et al., “Safety, activity, and immune correlates of anti-PD-1 antibody in cancer,” New England Journal of Medicine, Jun. 2012, 366(26):2443-54.
[cited by applicant]
UniProt ID No. P37173, “TGF-beta receptor type-2,” Oct. 17, 2006, 20 pages.
[cited by applicant]
UniProt ID No. P78324, “Tyrosine-protein phosphatase non-receptor type substrate 1,” Mar. 28, 2003, 13 pages.
[cited by applicant]
Wang et al., “HCB101: A safe and effective ligand trap therapeutic targeting the CD47-SIRPa signaling pathway for cancer treatment,” Abstract, Journal of Immunotherapy, Nov. 2022, 10(2):A1-595, 1 page.
[cited by applicant]
Weiskopf et al., “Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies,” Science. Jul. 2013, 341(6141):88, 13 pages.
[cited by applicant]
Xue et al., “Transforming growth factor-β: a multifunctional regulator of cancer immunity,” Cancers, Oct. 2020, 12(11):3099, 32 pages.
[cited by applicant]
Yanagita et al. “Anti-SIRPα antibodies as a potential new tool for cancer immunotherapy,” JCI Insight, Jan. 2017, 2(1), 16 pages.
[cited by applicant]
PCT International Preliminary Report on Patentability in International Appln. No. PCT/US2022/052373, mailed on Jul. 4, 2024, 10 pages.
[cited by applicant]
PCT International Preliminary Report on Patentability in International Appln. No. PCT/US2022/053125, mailed on Aug. 2, 2024, 8 pages.
[cited by applicant]
Brinkmann et al., “The making of bispecific antibodies,” Mabs, Feb. 2017, 9(2):182-212.
[cited by applicant]
Gulley et al., “Dual inhibition of TGF-β and PD-L1: a novel approach to cancer treatment,” Molecular Oncology, Jun. 2022, 16(11):2117-34.
[cited by applicant]
Ke et al., “HX009, a novel BsAb dual targeting PD1 x CD47, demonstrates potent anti-lymphoma activity in preclinical models,” Scientific Reports, Apr. 2023, 13(1):5419, 12 pages.
[cited by applicant]
Liu et al., “Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses,” Mabs, Feb. 2018, 10(2) 315-24.
[cited by applicant]
PCT International Search Report and Written Opinion in International Appln. No. PCT/CN2024/096554, mailed on Sep. 5, 2024, 16 pages.
[cited by applicant]
Pettinato, “Introduction to antibody-drug conjugates. Antibodies,” Oct. 2021, 10(4):42, 11 pages.
[cited by applicant]
Wang et al., “Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity, ” Cancer Immunology, Immunotherapy, Feb. 2021, 70:365-76.
[cited by applicant]
EP Partial Supplementary European Search Report in European Appln. No. 22912284.1, mailed on Mar. 31, 2025, 21 pages.
[cited by applicant]
EP Office Action in European Appln. No. 24150099.0, mailed on Dec. 17, 2017, 8 pages.
[cited by applicant]
Uniprot ID No. A0A6P8PA34, “Serine/threonine-protein kinase receptor,” Dec. 14, 2022, 7 pages.
[cited by applicant]
PCT International Preliminary Report on Patentability in International Appln. No. PCT/CN2023/140179, mailed on Jul. 3, 2025, 8 pages.
[cited by applicant]
PCT International Preliminary Report on Patentability in International Appln. No. PCT/CN2024/096554, mailed on Dec. 2, 2025, 9 pages.
[cited by applicant]
EP Extended European Search Report in European Appln. No. 24737660.1, mailed on Feb. 10, 2026, 10 pages.
[cited by applicant]